AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets, Price Target Unchanged at $66.00
ByAinvest
Wednesday, Jul 16, 2025 2:59 am ET1min read
BioXcel Therapeutics (BTAI) received a "Buy" rating from Lucid Capital Markets with a $66.00 price target. Analyst Elemer Piros reaffirmed the rating, highlighting the company's momentum and potential growth. The average one-year price target from 5 analysts is $9.40, indicating a 319.64% upside from the current price. The consensus recommendation is "Outperform" with a 2.5 rating from 4 brokerage firms.
BioXcel Therapeutics, Inc. (BTAI) has received a positive update from Lucid Capital Markets, which reaffirmed its "Buy" rating for the company's stock. The analyst, Elemer Piros, highlighted the company's momentum and potential for growth, with a price target of $66.00. This rating reflects a steady outlook on BTAI's market performance [2].The one-year price target from five analysts averages at $9.40, indicating a significant upside of 319.64% from the current price of $2.24. This optimism is further bolstered by the consensus recommendation of "Outperform" from four brokerage firms, with an average rating of 2.5 [2].
The company's stock has been performing well, with analysts noting its favorable trial developments, particularly for its BXCL501 treatment. The Data Safety Monitoring Board (DSMB) recently approved the continuation of the SERENITY At-Home pivotal Phase 3 safety trial without modifications. This positive recommendation is a significant milestone for BTAI, as it paves the way for further clinical trials and potential market approvals [3].
BioXcel Therapeutics, Inc. is a Connecticut-based biopharmaceutical company that employs artificial intelligence to develop medicines in neuroscience and immuno-oncology. The company's use of AI in drug development positions it well in the growing AI and biotech sectors.
References:
[1] https://finance.yahoo.com/quote/BTAI/analysis/
[2] https://www.gurufocus.com/news/2978384/btai-bioxcel-therapeutics-receives-steady-buy-rating-from-lucid-capital-markets-btai-stock-news
[3] https://finance.yahoo.com/news/bioxcel-therapeutics-inc-btai-retains-232723250.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet